scholarly journals Comparison of Management of Depression in Different Age Groups: A Clinical Study

2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Anil Kumar Jain ◽  
Sandeep Kumar
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Age Groups ◽  
Young Patients ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Group Iii ◽  
Group I ◽  
Group Ii ◽  
The Difference

Background: Depression has been considered 4th causes of diseases worldwide according to World Health Organization (WHO). Depression requires proper diagnosis and management in different age groups. This study was conducted to evaluate the comparison of management of depression in different age groups, especially in young, middle and older age groups. Materials & Methods: This study was conducted in department of Psychiatry in year 2010. Those who were diagnosed and obtained treatment in year 2010 were enrolled and considered for the study. It consisted of 240 patients diagnosed with depression. They were divided into 3 groups depending upon age. Group I (Young group) – <40 years, group II (Middle aged group) – 40-60 years and group III (Older group)- >60 years. Each group contained 80 patients each. We evaluated number and type of drugs used for antidepressant treatment, their effectiveness (psychotherapy, pharmacotherapy, combination of psychotherapy and pharmacotherapy, spontaneously remission). Results: This study comprised of 240 patients. They were divided into 3 groups depending upon age. Group I (Young group) – <40 years, group II (Middle aged group)- 40-60 years and group III (Older group)- >60 years. Each group contained 80 patients each. The difference was no significant (P<0.05). 40% of patients in group I, 45% in group II and 65% in group III were of 1 drug only. 20% in group I, 25% in group II and 10% in group III was on 2 drugs. 10% in group I, 15% in group II and 5% in group III was on 3 drugs. Patients were on no drug in group I (30%), group II (15%) and group III (10%). The difference was no significant (P<0.05). 40% of patients were on selective serotonin reuptake inhibitors (SSRI), 25% were on combination of selective serotonin reuptake inhibitors and benzodiazepines (BDZ) and 35% were on benzodiazepines only. In group II, 35% of patients were on selective serotonin reuptake inhibitors (SSRI), 40% were on combination of selective serotonin reuptake inhibitors and benzodiazepines (BDZ) and 25% were on benzodiazepines only. In group III, 40% of patients were on selective serotonin reuptake inhibitors (SSRI), 42% were on combination of selective serotonin reuptake inhibitors and benzodiazepines (BDZ) and 12% were on benzodiazepines only. The difference was significant in all the groups regarding combination therapy and benzodiazepines (P<0.05). Type of therapy used in all groups was either general practitioner (GP) support, psychotherapy, pharmachotherapy, pharmachotherapy or GP support, combination of psychotherapy and pharmachotherapy. There was significant difference in all the groups regarding combination therapy (P<0.01). Conclusion: Young patients usually do not take any medication in depression. Older take more than 1 or 2 medication at same time. Young patients were more on SSRI while older were equally on SSRI and combination of SSRI & BDZ.

UTILIZATION AND EVALUATION OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS(SSRI's) IN PSYCHIATRY PATIENTS OF SECONDARY CARE TEACHING HOSPITAL OF SOUTH INDIA

2021 ◽  
pp. 1-5
Author(s):  
Mylam Suma Bhavana ◽  
Murthysetty Likhitha ◽  
Thirugabathina Swathi ◽  
A.C Nikila Teja ◽  
Dr. K. Harinadha Baba ◽  
...  
Keyword(s):  
Teaching Hospital ◽  
Secondary Care ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
South India ◽  
Age Groups ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Care Teaching ◽  
Number Of Patients

Selective serotonin reuptake inhibitors (SSRI's) are the most commonly prescribed antidepressants. They are mainly prescribed to treat depression. SSRI's are considered to be safer and generally cost effective when compared to some newer antidepressant classes. SSRI's acts by inhibiting the serotonin transporter (SERT) at the presynaptic axon terminal. A number of factors must be considered when evaluating SSRI's. An SSRI drug utilization study is performed for further evaluation. The study was a prospective obs Methodology: ervational study on “Utilization and Evaluation of SSRI's in Psychiatry Patients”, which was carried out in the 'Department of Psychiatry' in a Secondary care teaching hospital of South India. Study the maximum number of patients was 786 and the age groups of 981 out of which m Results: aximum were of age group 46-54 and minimum were above 60, the female were more suffered in that maximum were married and the educational levels of the patients were mostly secondary, the hygienic conditions, surroundings and cleanliness were good. Discussion: Recent studies also found that mostly used SSRIs are Fluoxetine, Paroxetine, Citalopram and Sertraline. We found that in our hospitals the data reveals the status for some mostly used Fluoxetine as 386 (49.10%) and Paroxetine 288 (36.64%). Conclusion: Our study concluded that most of the patients suffered with psychological conditions and symptoms are considered. After using SSRI their overall effect in the patient health and outcome was observed with better outcome.

scholarly journals Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

2001 ◽  
Vol 178 (3) ◽  
pp. 234-241 ◽  
Author(s):  
Michael E. Thase ◽  
A. Richard Entsuah ◽  
Richard L. Rudolph
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Rating Scale ◽  
Depression Score ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Double Blind ◽  
Remission Rates ◽  
The Difference ◽  
Definition Of

BackgroundIt had been suggested that the antidepressant venlafaxine, which inhibits reuptake of both serotonin and (at higher doses) noradrenaline, may result in better outcomes than treatment with selective serotonin reuptake inhibitors (SSRIs).AimsTo compare remission rates during treatment with SSRIs or venlafaxine.MethodData from eight comparable randomised, double-blind studies of major depressive disorder were pooled to compare remission rates (Hamilton Rating Scale for Depression score ≤ 7) during treatment with venlafaxine (n=851), SSRIs (fluoxetine, paroxetine, fluvoxamine; n=748) or placebo (four studies; n=446).ResultsRemission rates were: venlafaxine, 45% (382/851); SSRIs, 35% (260/748); placebo, 25% (110/446) (P < 0.001; odds ratio for remission is 1.50 (1.3–1.9), favouring venlafaxine v. SSRIs). The difference between venlafaxine and the SSRIs was significant at week 2, whereas the difference between SSRIs and placebo reached significance at week 4. Results were not dependent on any one study or the definition of remission.ConclusionsRemission rates were significantly higher with venlafaxine than with an SSRI.

Sign in / Sign up

Export Citation Format

Share Document